NCT03219333 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 125
- group Id
- BG001
- value
- 89
- group Id
- BG002
- value
- 214
- units
- Participants
- groups
- description
- Participants in Cohort 1 had received prior treatment with platinum-containing chemotherapy. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.
- id
- BG000
- title
- Enfortumab Vedotin - Cohort 1
- description
- Participants in Cohort 2 had received no platinum-containing chemotherapy were ineligible for treatment with cisplatin at the time of enrollment. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.
- id
- BG001
- title
- Enfortumab Vedotin - Cohort 2
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 40
- upper Limit
- 84
- value
- 69.0
- group Id
- BG001
- lower Limit
- 49
- upper Limit
- 90
- value
- 75.0
- group Id
- BG002
- lower Limit
- 40
- upper Limit
- 90
- value
- 72.0
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 37
- group Id
- BG001
- value
- 23
- group Id
- BG002
- value
- 60
- title
- Female
- measurements
- group Id
- BG000
- value
- 88
- group Id
- BG001
- value
- 66
- group Id
- BG002
- value
- 154
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 6
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 118
- group Id
- BG001
- value
- 83
- group Id
- BG002
- value
- 201
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 7
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 31
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 106
- group Id
- BG001
- value
- 62
- group Id
- BG002
- value
- 168
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 13
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 117
- group Id
- BG001
- value
- 57
- group Id
- BG002
- value
- 174
- title
- North America
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 14
- title
- Europe
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 26
- title
- East Asia
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 40
- group Id
- BG001
- value
- 37
- group Id
- BG002
- value
- 77
- title
- 0
- categories
- measurements
- group Id
- BG000
- value
- 85
- group Id
- BG001
- value
- 41
- group Id
- BG002
- value
- 126
- title
- 1
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 11
- title
- 2
- description
- ECOG performance status was used to assess participants disease progression, and ability to carry out daily living activities. 0=Normal activity; 1=Symptoms but ambulatory; 2=In bed \<50% of the time; 3= In bed \>50% of the time; 4=100% bedridden; 5=Dead
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status
- unit Of Measure
- Participants
- population Description
- Safety population included all participants who received any amount of enfortumab vedotin.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 125
- group Id
- BG001
- value
- 89
- group Id
- BG002
- value
- 214
- units
- Participants
- groups
- description
- Participants in Cohort 1 had received prior treatment with platinum-containing chemotherapy. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.
- id
- BG000
- title
- Enfortumab Vedotin - Cohort 1
- description
- Participants in Cohort 2 had received no platinum-containing chemotherapy were ineligible for treatment with cisplatin at the time of enrollment. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.
- id
- BG001
- title
- Enfortumab Vedotin - Cohort 2
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 40
- upper Limit
- 84
- value
- 69.0
- group Id
- BG001
- lower Limit
- 49
- upper Limit
- 90
- value
- 75.0
- group Id
- BG002
- lower Limit
- 40
- upper Limit
- 90
- value
- 72.0
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 37
- group Id
- BG001
- value
- 23
- group Id
- BG002
- value
- 60
- title
- Female
- measurements
- group Id
- BG000
- value
- 88
- group Id
- BG001
- value
- 66
- group Id
- BG002
- value
- 154
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 6
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 118
- group Id
- BG001
- value
- 83
- group Id
- BG002
- value
- 201
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 7
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 31
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 106
- group Id
- BG001
- value
- 62
- group Id
- BG002
- value
- 168
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 13
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 117
- group Id
- BG001
- value
- 57
- group Id
- BG002
- value
- 174
- title
- North America
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 14
- title
- Europe
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 26
- title
- East Asia
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 40
- group Id
- BG001
- value
- 37
- group Id
- BG002
- value
- 77
- title
- 0
- categories
- measurements
- group Id
- BG000
- value
- 85
- group Id
- BG001
- value
- 41
- group Id
- BG002
- value
- 126
- title
- 1
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 11
- title
- 2
- description
- ECOG performance status was used to assess participants disease progression, and ability to carry out daily living activities. 0=Normal activity; 1=Symptoms but ambulatory; 2=In bed \<50% of the time; 3= In bed \>50% of the time; 4=100% bedridden; 5=Dead
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status
- unit Of Measure
- Participants
- population Description
- Safety population included all participants who received any amount of enfortumab vedotin.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle